Pharmaceutical Executive Highlights ixlayer Survey Findings on the Rise of Direct-to-Patient Programs
Pharmaceutical Executive recently featured ixlayer’s latest survey of pharmaceutical executives, revealing just how rapidly direct-to-patient (DTP) programs are becoming standard practice across the industry.
According to the survey, 94% of pharma companies are either already running, launching, or actively exploring DTP initiatives—confirming that direct-to-patient engagement has evolved from an experimental concept to a core strategic pillar for most organizations.
Key findings from the report include:
- 42% of pharma companies already operate DTP programs.
- 30% plan to launch one within the next year.
- 21% are currently exploring DTP implementation.
- Nearly half of respondents believe DTP programs will become standard across most brands within the next five years.
The article notes that the motivation behind this shift is clear: pharma leaders are looking for ways to reduce patient friction, accelerate time to therapy, and improve the patient experience—all while maintaining compliance and trust.
“The common thread is direct-to-patient solutions that feel simple and seamless for the patient, connect back to their doctor (or help them find one) and make pharma marketing initiatives more actionable, ultimately driving better health outcomes as well as commercial success,”
— Matthew Walsh, General Manager, Biopharma at ixlayer, in the PharmExec article.
Pharmaceutical Executive highlighted that while many early programs focused on patient support or affordability tools, the next generation of DTP strategies will integrate digital diagnostics, telehealth, and fulfillment to create a complete, measurable care pathway.
The takeaway: DTP programs are no longer “nice-to-have” pilots. They’re a signal that pharma is re-engineering how it connects patients to care, and ixlayer is helping power that transformation.
Read the research report from ixlayer’s pharma executive survey: Closing the Awareness Gap: What Pharma Executives and Patients Expect from Direct-to-Patient Programs in 2025
Read Pharmaceutical Executive’s full article: https://www.pharmexec.com/view/ixlayer-survey-94-leaders-direct-to-consumer-programs
About ixlayer
ixlayer has the only end-to-end, direct-to-patient platform built for biopharma and optimized for patient choice. We help biopharma companies connect with patients from testing to treatment with speed, transparency, control and impact.
